Lukas Bunse
@lukasbunse.bsky.social
Neurologist and Immunologist at University Heidelberg and DKFZ with a focus on immunotherapy and cellular therapy of brain tumors and CNS autoimmunity
Heading back from the fourth and last plenary Glioresolve @glioresolve.bsky.social Meeting from Dublin @rcsi.bsky.social! Terrific to see how our doctoral network students advance science in the field of glioblastoma and develop their careers - can’t wait to hear more from them in the future!
Type I IFN drives T cell responses to amyloid beta in the central nervous system @natcomms.nature.com @lukasbunse.bsky.social www.nature.com/articles/s41...
Advances in NeuroImmunoOncology: Tyler E. Miller, David Gutmann, and Lukas Bunse addressed this topic in a plenary session at the AACR Special Conference on Brain Cancer. #AACRbrain26 @dhgutmann.bsky.social @lukasbunse.bsky.social
Advances in NeuroImmunoOncology: Tyler E. Miller, David Gutmann, and Lukas Bunse will address this topic in a plenary session at the AACR Special Conference on Brain Cancer (March 23-25, 2026; Philadelphia). Learn more: buff.ly/xqEJWTD #AACRbrain26 @dhgutmann.bsky.social @lukasbunse.bsky.social
For his investigations how the body's own immune system can be supported in fighting brain tumors, Lukas Bunse (DKFZ & University Medical Centre Mannheim) has been awarded the Lautenschläger Prize for Young Scientists. 👏 @lukasbunse.bsky.social t1p.de/4w2f5
Lautenschläger Prize for Young Scientists 2025 awarded to Lukas Bunse
As a clinician scientist at the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University, neurologist Lukas Bunse is investigating how the body's own immune syste...
t1p.de
The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/... Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.
The immunology of brain tumors
The cellular and molecular determinants of the antigenicity of brain tumors and the immunosuppressive brain tumor microenvironment are reviewed.
science.org
Our CIMT coverage is out! 👉 Go to bit.ly/3SUQCOX to read a summary of select talks. #CIMT2025 Featured are: @ki.se @unileiden.bsky.social @ethz.ch @niaidnews.bsky.social @dkfz.bsky.social @lukasbunse.bsky.social @biontech.bsky.social
Herzlichen Glückwunsch: 🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social 🏆️ Dr. Lukas Bunse @lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6
Huge congrats @lukasbunse.bsky.social, so well deserved, fantastic achievement. @hlsalliance.bsky.social @cn-hd.bsky.social @neurooncologyhd.bsky.social @mctneuroscience.bsky.social @platten-lab.bsky.social
Deutsche Forschungsgemeinschaft@dfg.de · last yr.Herzlichen Glückwunsch: 🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social 🏆️ Dr. Lukas Bunse @lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6
PTPRZ1 was upregulated in GBM samples and was associated with cell stemness (GSC score). [...] bit.ly/416M1wV @lukasbunse.bsky.social
Congratulations to David for being a finalist for the YPIC #proteomics Fund! We are happy to support his application at the Immunopeptidomics Platform HI-TRON and hope the fund will make this breakthrough project possible in collab with David from @lukasbunse.bsky.social lab at @dkfz.bsky.social
@ypic.bsky.social · last yr.Meet YPIC Student Proteomics Fund finalist David Palmero Cantón! David is a biotechnologist by training who specialized in cancer research during his master’s studies and is now pursuing his PhD at DKFZ-German Cancer Research Center.
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen www.nature.com/articles/s41... @lukasbunse.bsky.social @naturecomms.bsky.social
1/2 Super excited to see this finally out @naturecomms.bsky.social ! We developed an off-the-shelf T cell receptor T cell therapy for patients with glioblastoma from a peptide vaccinated patient. Looking very much forward to its translation within DKTK supported by HI-TRON!
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen - Nature Communications
Vaccination in glioblastomas does lead to the emergence of tumour-antigen-specific T cells but T cell dysfunction, poor tumour infiltration and persistence hinder efficient tumour killing. Here author...
nature.com
Great fun to write this perspective with @lukasbunse.bsky.social @platten-lab.bsky.social @dkfz-iic.bsky.social @dkfz.bsky.social on a highly interesting study by the Bardeesy Lab. This study provides additional mechanistic rationale to combine IDH inhibitors with T cell activating therapies.
NEJM.org@nejm.org · 2y agoA recent study unpicks a key immune-mediated mechanism of mutant IDH–blocking drugs such as vorasidenib in the treatment of IDH-mutant glioma. Learn more in a new Clinical Implications of Basic Research article: nej.md/4f3dIMf #MedSky
Could not be any prouder. Stellar work, fantastic lecture - day to remember. Welcome to the faculty @lukasbunse.bsky.social.
The Platten Lab@platten-lab.bsky.social · 2y agoToday we congratulate @lukasbunse.bsky.social for his successful dissertation and his inaugural lecture at umm Mannheim. Congratulations!!
